Curasan Overview
- Year Founded
-
1988
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Buyout/LBO
- Investors
-
2
Curasan General Information
Description
Developer of biomaterials and medical devices designed for bone and tissue regeneration. The company focuses on biomimetic bone grafting materials for use in orthopedics, traumatology, spine surgery, and dental implantology, providing healthcare industry with a product range including wound healing and osteoarthritis therapy.
Contact Information
Website
www.curasaninc.comCorporate Office
- 1768 Heritage Center Drive
- Suite 204
- Wake Forest, NC 27587
- United States
Corporate Office
- 1768 Heritage Center Drive
- Suite 204
- Wake Forest, NC 27587
- United States
Curasan Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Buyout/LBO | 16-Dec-2020 | Completed | Generating Revenue | |||
5. Bankruptcy: Admin/Reorg | 01-Jun-2020 | Completed | Bankruptcy: Admin/Reorg | |||
4. PIPE | 12-Dec-2017 | Completed | Profitable | |||
3. PIPE | 19-Dec-2016 | Completed | Profitable | |||
2. PIPE | 28-May-2015 | $1.14M | $17.3M | Completed | Profitable | |
1. IPO | 20-Jul-2000 | $21.9M | $16.2M | Completed | Startup |
Curasan Patents
Curasan Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9907884-B2 | Biodegradable composite material | Active | 31-May-2011 | ||
US-20140170202-A1 | Biodegradable composite material | Active | 31-May-2011 | ||
EP-2714112-A2 | Biodegradable composite material | Active | 31-May-2011 | ||
EP-2714112-B1 | Biodegradable composite material | Active | 31-May-2011 | ||
EP-2529764-A1 | Biodegradable composite material | Inactive | 31-May-2011 | A61L27/56 |
Curasan Signals
Curasan Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Donau Invest Beteiligungs | Venture Capital | Majority | ||
New Frontier Health | PE-Backed Company | Minority |
Curasan Investments & Acquisitions (4)
Curasan’s most recent deal was a Joint Venture with Novaxomx. The deal was made on 21-Mar-2022.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Novaxomx | 21-Mar-2022 | Joint Venture | Biotechnology | ||
Jeder | 03-Jul-2019 | Merger/Acquisition | Surgical Devices | ||
RIEMSER Arzneimittel (Dental Division) | 18-Mar-2013 | Merger/Acquisition | Medical Supplies | ||
Pro-Tec Medizinische Produkte | 21-Mar-2001 | Merger/Acquisition | Biotechnology |
Curasan ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Affiliates
Subsidiaries (1)
Name | Industry | Location | Year Founded |
---|---|---|---|
Jeder | Vienna, Austria | 2010 |
Curasan FAQs
-
When was Curasan founded?
Curasan was founded in 1988.
-
Where is Curasan headquartered?
Curasan is headquartered in Wake Forest, NC.
-
What is the size of Curasan?
Curasan has 40 total employees.
-
What industry is Curasan in?
Curasan’s primary industry is Medical Supplies.
-
Is Curasan a private or public company?
Curasan is a Private company.
-
What is Curasan’s current revenue?
The current revenue for Curasan is
. -
How much funding has Curasan raised over time?
Curasan has raised $23.4M.
-
Who are Curasan’s investors?
Donau Invest Beteiligungs and New Frontier Health have invested in Curasan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »